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Abstract
Background: Although recent studies have suggested that adherence to antihypertensive treatment reduced
stroke incidence, the relationship of adherence to antihypertensives with stroke severity has not been studied.
This study attempted to know whether nonadherence before stroke is associated with initial severity of acute
ischemic stroke.
Methods: Consecutive patients with acute ischemic stroke were identified in Soonchunhyang University Hospital
from Mar 2005 to Aug 2014, excluding the cases without hypertension or information of antihypertensive adherence.
We compared the mean of National Institute of Health Stroke Scale (NIHSS) score between adherence groups and
insufficient medication group, and additionally in each stroke subtype. Multiple linear regression model was established
for initial NIHSS score adjusting alleged factors linked to stroke severity.
Results: Initial NIHSS score were higher in insufficient medication group than adherence group (6.5 ± 7.2 VS 5.4 ± 5.7,
P = .11). In large artery atherosclerosis (LAA) and small vessel occlusion (SVO), initial NIHSS score were significantly
higher in insufficient medication group (6.1 ± 6.5 VS 4.4 ± 4.4, P = .004 for LAA; 3.8 ± 3.5 VS 2.7 ± 1.8, P = .014 for SVO).
In multiple linear regression model, insufficient medication to antihypertensives had a significant effect on NIHSS score
(t = 3.417, P = .001) after adjusting covariates.
Conclusion: Insufficient medication of antihypertensives before stroke was independently associated with the severity
of acute ischemic stroke. Further studies with prospective designs are warranted to evaluate clinical implication of
adherence to antihypertensives for ischemic stroke.
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Background
Benefits of blood pressure lowering for primary stroke
risk reduction are broadly consistent across a range of
different population [1–4]. Recent studies support that
more intensive control of blood pressure reduces risk of
stroke more than less intensive control [5–8]. However,
high adherence to antihypertensive treatment in terms
of reduction of cardiovascular events has been relatively
underscored in the field of evidence-based therapies of
population [9].
Adherence to antihypertensive is closely related to the
time within therapeutic range, and may influence on the
cardiovascular prognosis [10]. The associations between
non-adherence and stroke events followed a dose-
response pattern, and the poorer the adherence, the
greater the risk of death and hospitalization due to
stroke [11]. The World Health Organization (WHO)
had estimated that between 20–80 % of patients re-
ceiving treatment for hypertension are adherent [12].
In Korea, among people aged more than 30 years
with hypertension, 61.9 % were on regular treatment,
and only 43.6 % had their blood pressure under con-
trol [13]. Nonadherence to antihypertensive treatment
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is a common problem for cardiovascular prevention
in Korean population.
The initial stroke severity has been reported as the most
important predictor for poststroke outcome [14–16], and
is correlated with stroke subtypes [17]. A few study re-
ported a controversial class effect of antihypertensive
drugs [18, 19] and the combination with antiplatelet or
statin on stroke severity [20], but the relationship between
the pre-stroke non-adherence to antihypertensives and
stroke severity has been largely unknown.
This study aimed to investigate whether nonadherence
to antihypertensives prior to acute ischemic stroke is




A total 2335 consecutive patients with first acute (<7 days)
ischemic stroke or imaging-positive transient ischemic
attack were registered in Soonchunhyang University
Hospital from Mar 2005 through Aug 2014. This web-
based registry contains clinical characteristics, laboratory/
imaging findings, and cardiovascular outcomes after
discharge [21]. The study design was approved by the
Soonchunhyang institutional review board before in-
vestigation. Hypertension was detected in 1660 (71.1 %)
patients. The diagnostic criteria of hypertension were 1)
history of diagnosis prior to acute ischemic stroke or 2)
systolic/diastolic blood pressure (SBP/DBP) of ≥160/95
mmHg in at least two subsequent measurement after
stable state of acute stroke or 3) evidence of left ventricu-
lar hypertrophy in echocardiography or hypertensive ret-
inopathy during hospitalization. LVH with diabetes or
other metabolic causes was excluded in case of no history
of hypertension.
Data collection and workup
Data were prospectively collected including history of
hypertension, medication history, vascular risk factors,
laboratory findings, stroke subtypes, initial National
Institute of Health Stroke Scale (NIHSS) Score. Adher-
ence to antihypertensives during the last one month
were captured by patient’s or caregiver’s information,
and were categorized into two groups: adherence
(regular medication) and insufficient medication (diagnosed
but no medication, irregular medication, and undetected
before index stroke). The patients who took medications
more than 80 % of the last one month were categorized as
regular medication. The cases with missing data for adher-
ence to antihypertensives prior to acute ischemic stroke
were excluded (n = 93, 5.6 %).
Stroke subtypes were determined by extensive workups
including magnetic resonance imaging/angiography, echo-
cardiography, and Holter monitoring in all patients: large
artery atherosclerosis (LAA), small vessel occlusion
(SVO), cardioembolism (CE), and undetermined etiology
(SUE). Stroke with other determined etiology were ex-
cluded (n = 29). Finally, 1538 cases were analyzed.
Statistical analysis
Categorical variables were reported as frequency and
continuous variables as mean ± standard deviation. Chi-
square test was used to determine the relationship with
categorical variables, and student T-test to compare the
means of continuous variables between adherence and
insufficient medication group. The difference of NIHSS
score between adherence group and insufficient medica-
tion group were determined by T-test in each stroke
subtype. Multiple linear regression model was estab-
lished for initial NIHSS score adjusting covariates which
have an influence on initial stroke severity in univariate
analysis and previous reports. Statistical significance was
defined as P <0.01 in multiple linear regression. All stat-
istical analyses were done with SPSS 18.0 for Windows
(Chicago, USA).
Results
The patients who had taken antihypertensives regularly
before stroke (adherence group) were 1232 (80.1 %).
Insufficient medication group had 306 (19.9 %) patients:
diagnosed but no medication (n = 54), irregular medica-
tion before acute stroke (n = 164), and diagnosed at ad-
mission (n = 88). The average age were 69.6 ± 11.5 in
adherence group while those in insufficient medication
group were 66.1 ± 12.2 (P < .001). The fraction of insuffi-
cient medication group were larger in female than male
(22.1 % VS 18.1 %, P = .054). Insufficient medication
group had higher initial NIHSS score than adherence
group (6.5 ± 7.2 VS 5.4 ± 5.7, P = .11). The baseline char-
acteristics between adherence and insufficient medica-
tion group were depicted in Table 1.
Mean NIHSS scores among stroke subtypes were com-
pared in Table 2. Cases with missing data for TOAST
classification were not included (n = 17). NIHSS score
were significantly higher in insufficient medication group
in LAA and SVO: 6.1 ± 6.5 VS 4.4 ± 4.4, P = .004 for
LAA; 3.8 ± 3.5 VS 2.7 ± 1.8, P = .014 for SVO. There was
a tendency of higher NIHSS score of insufficient medica-
tion group in CE (12.7 ± 11.0 VS 9.3 ± 7.4, P = .141) and
SUE (8.4 ± 8.3 VS 7.0 ± 6.8, P = .004).
In multiple linear regression model, R square was 0.653,
and residual was independent (Durbin Watson = 1.813).
The fitness of regression model was good (F = 18.716,
P < .001). The strongest factor which influence on NIHSS
score was atrial fibrillation (t = 10.944, P < .001). Age
(t = 3.266, P < .001), initial systolic blood pressure (t =
3.396, P = .001) and previous stroke history (t = 2.717,
P = .007) were also significant. Insufficient medication
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to antihypertensives had an independent effect on
NIHSS score (t = 3.417, P = .001) (Table 3).
Discussion
This study demonstrates that low antihypertensive medi-
cation adherence was related to severe acute ischemic
stroke. Nonadherence is an important and very amen-
able factor to change among cardiovascular risk factors
for hypertensive patients [22]. Self-reported adherence
to cardiovascular medications in patients who have cor-
onary artery disease is less than 40 % [23]. However, the
nonadherence to antihypertensive for primary cardiovas-
cular prevention would be as high as 50 % [24]. The
efficacy of antihypertensives has been evaluated in ran-
domized clinical trials (RCTs), but in actual practice,
many patients who would be excluded from RCTs re-
ceive medication for a long time, and may not be as
adherent with medication as those included in RCTs
[25]. A tertiary medical center in Korea reported that
average non-compliance to the single drug antihyperten-
sive regimen was 16 % in the cardiology practice [26]. In
general Korean population, however, about one third are
not on regular antihypertensive treatment [13]. The
overall rate of nonadherence was about 20 % in our
10-year observation study, and the fraction of nonad-
herence was higher in female.
Assessing adherence to hypertensive therapy for car-
diovascular prevention is a complex process influenced
by multiple factors [27]. Previous studies differentiates
between adherent and nonadherent patients by prescrip-
tion claim, drug refill, patients’ records, motivation and
knowledge [23, 28, 29]. This study collected data about
the regularity of medication by patient’s or caregiver’s
description during the last one month before acute is-
chemic stroke. Given an observational nature of our
study, this would lead to many epidemiological bias.
However, because complicated scales could not be
applied in the setting of acute stroke enrolling con-
secutive patients, we have used simple item to evaluate
adherence before stroke in registry system. Although
unrecognized hypertension should be considered separ-
ately from nonadherence to antihypertensives, this study
was to measure stroke severity in whom blood pressure
were not adequately controlled. Therefore, hypertension
diagnosed at admission were included within insufficient
medication group. Most previous study obtained the ad-
herence data at one point of several years before stroke
event [9, 11, 30], out study checked shortly before stroke
reflecting recent adherence.
The pathophysilogic mechanisms between uncon-
trolled hypertension and severe stroke needs to be stud-
ied. One previous study suggested that prestroke beta-
blocker use is related to less severe ischemic stroke by
sympatholytic effect [18]. High blood pressure can result
in increased glucocorticoid level and inflammatory
marker which can aggravate cell death in penumbra area
[31–34]. Reduction in arterial pressure by hydralazine
with hydrochlorothiazide or an angiotensin converting
Table 1 Baseline characteristics between adherence and
insufficient medication group
Characteristics Adherence
(n = 1232, 80.1 %)
Insufficient medication
(n = 306, 19.9 %)
P
Age, years 69.6 ± 11.5 66.1 ± 12.2 <.001
Sex, male 704 (57.1 %) 156 (51.0 %) .054
BMI (kg/m2) 24.0 ± 3.3 24.5 ± 3.6 .043
NIHSS, admission 5.4 ± 5.7 6.5 ± 7.2 .011
Initial SBP, mmHg 146.6 ± 26.4 151.6 ± 28.2 .004
Initial DBP, mmHg 85.8 ± 14.3 91.0 ± 15.6 <.001
Previous stroke
history
284 (23.1 %) 57 (18.6 %) .106
Previous antiplatelet 103 (8.7 %) 17 (5.6 %) .121
Previous statins 97 (7.9 %) 15 (4.9 %) .087
Antihypertensive
class
CCB 538 (43.7 %) 61 (37.2 %)a .135
BB 271 (22.0 %) 33 (20.1 %) .664
ARB 406 (33.0 %) 52 (31.7 %) .823
ACEI 117 (9.5 %) 23 (14.0 %) .103
Diuretics 303 (24.6 %) 34 (20.7 %) .323
Diabetes 546 (44.3 %) 133 (43.5 %) .839
Hyperlipidemia 302 (24.5 %) 152 (49.7 %) <.001
Current smoking 256 (20.8 %) 103 (33.7 %) <.001
Atrial fibrillation 323 (26.2 %) 48 (15.7 %) <.001
Total cholesterol,
mg/dL
167.0 ± 42.4 216.1 ± 44.2 <.001
Initial glucose, mg/dL 133.5 ± 60.5 141.0 ± 60.0 .082
Hemoglobin A1c, % 6.6 ± 1.5 6.9 ± 1.9 .011
Data are n (%) or mean ± SD values. P values for T-test and chi-square test
SBP systolic blood pressure, DBP diastolic blood pressure, CCB calcium channel
blocker, BB beta blocker, ARB angiotensin receptor blocker, ACEI angiotensin
converting enzyme inhibitor
aDenominator: nonadherent cases except unrecognized or no medication
Table 2 Mean NIHSS score among stroke subtypes
Stroke subtypes Case Adherence Insufficient medication P
Large artery
atherosclerosis
731 4.4 ± 4.4 6.1 ± 6.5 .004*
Small vessel
occlusion
260 2.7 ± 1.8 3.8 ± 3.5 .014*
Cardioembolism 214 9.3 ± 7.4 12.7 ± 11.0 .141
Undetermined
etiology
316 7.0 ± 6.8 8.4 ± 8.3 .194
Total 1521 5.5 ± 5.7 6.5 ± 7.2 .017
Data are mean ± SD values. P values for T-test within each stroke subtype
*P < .05
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enzyme inhibitor is protective against focal cerebral is-
chemia in stroke-prone spontaneously hypertensive rats
model [35]. Nonadherence to antihypertensive medica-
tion prior to first stroke was associated with a 5.7-fold
increased odds of fatal stroke during the year of death
and a two-fold increased risk of nonfatal stroke [11].
Higher odds of fatal stroke than that of nonfatal stroke
may indicate that nonadherence is closely related to
more severe stroke.
It is noteworthy that the achievement of target BP goal
is an important factor for preventing stroke. Although
there was a significant difference in the stroke severity
between adherence and insufficient medication groups,
mean SBP/DBP were higher in insufficient medication
group. The values of mean SBP/DBP which failed to
reach a target goal may influence on the severity of acute
ischemic stroke. However, the acute hypertensive re-
sponse is very common in acute stroke period (occurring
in >75 % of cases), and may be induced by increased
sympathoadrenal tone, direct brain injury, systemic con-
dition or stress response [36]. The difference of SBP/
DBP can be a consequence of more severe stroke in in-
sufficient group. For this reason a strict definition should
be needed for the “history of hypertension” in acute
stroke registry. The definition of hypertension in this
study was 160/95 instead of 140/90. In the Framing-
ham cohort, the “definite hypertension” was defined
as 160/95 [37]. Previous studies assessed the history
of stage II hypertension as blood pressure ≥160/95
mm Hg or use of antihypertensive medicine at base-
line questionnaire [38].
Our study has several limitations. First, the data of
insufficient medication were captured only for antihy-
pertensives, but not for antiplatlets, antidiabetics or lipid
lowering agents. Prestroke antiplatelets may be associ-
ated with stroke severity [39, 40]. However, the propor-
tion of antiplatelet user before stroke was neither high
nor different between the two groups in our study popu-
lation (8.7 % VS 5.6 %, P = .121). Moreover, individual
adherences to medications were not different across vas-
cular risk factors [19]. Second, this study was single
center-based, although the number of subjects was
enough to be compared with previous studies. Our re-
sults need external validation to confirm the association
between insufficient medication and stroke severity.
Third, it is known that the NIHSS score does not gener-
ally show normal distribution to be an outcome variable
in linear regression model. However, the case number of
our study was sufficiently large with good explanation
power and model fitness (R square = 0.653; F = 18.716,
P < .001), and there was no multicollinearity between var-
iables in our regression model (VIF <2). Finally, in our
study, insufficient medication patients had more smokers
and higher serum cholesterol level. Although the associ-
ation between insufficient medication and stroke severity
was significant after adjusting these variables, the social
habit and healthy conditions should be considered as in-
fluencing factors on nonadherence in Korean.
Conclusion
In conclusion, our study in the patients with acute ische-
mic stroke, insufficient medication to antihypertensives
before stroke was independently associated with stroke
severity. Further prospective cohort are warranted to
evaluate clinical implication of adherence to medications
for prevention of cardiovascular disease.
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Table 3 Multiple linear regression model for initial NIHSS in acute ischemic stroke
Dependent variable Independent variable B β t P-value VIF
NIHSS Constant −2.23
Age .050 .097 3.266 .001* 1.292
Male −.872 −.071 −2.428 .015 1.258
Body Mass Index −.051 −.028 −1.050 .294 1.050
Previous stroke history 1.056 .073 2.717 .007* 1.052
Atrial fibrillation 4.197 .294 10.944 <.001* 1.065
Current smoking .953 .067 2.255 .024 1.320
Initial SBP .021 .090 3.396 .001* 1.040
Total cholesterol .000 −.002 −.054 .957 1.278
Hemoglobin A1c .200 .053 2.019 .044 1.028
Insufficient medication 1.489 .099 3.417 .001* 1.230
*P < .01
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